RMRakesh Malhotra

Rakesh Malhotra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rakesh Malhotra has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Peter Kotanko

    Renal Research Institute, New York, NY, USA

    3 shared publications
  • Armin Ahmadi

    University of California San Diego, United States

    2 shared publications
  • Joachim H. Ix

    Division of Nephrology and Hypertension, Department of Medicine, University of California-San Diego, San Diego, California; Nephrology Section, Veteran Affairs San Diego Healthcare System, La Jolla, California

    2 shared publications
  • Pranav S. Garimella

    Division of Nephrology and Hypertension, Department of Medicine, University of California-San Diego, San Diego, California

    2 shared publications
  • T. Alp Ikizler

    Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee

    2 shared publications
  • Tushar Chopra

    Division of Nephrology, Department of Medicine, University of Virginia, Charlottesville, Virginia

    2 shared publications

Latest Publications

  • Open Access

    Physical Activity Fragmentation and All-Cause Mortality in Hemodialysis Patients: Insights From Fitbit Study

    by Armin Ahmadi, Subhasis Dasgupta, Maggie Han, Peter Kotanko, Rakesh Malhotra

  • Open Access

    Associations of Biomarkers of Kidney Tubule Health with Retinal Microvascular Signs

    by Armin Ahmadi, Hassan Gorji, Sanskrita Shashikant, Ronit Katz, Alfons J.H.M. Houben, Robert N. Weinreb, Matthew Allison, Stacy M. Meuer, Barbara E. Klein, Mary Frances Cotch, et al.

    Key Points: Kidney injury molecule-1 and soluble urokinase plasminogen activator receptor are associated with retinal microvascular changes in individuals without CKD, diabetes, or cardiovascular disease. Tubule biomarkers may reveal microvascular pathways linking kidney dysfunction to cardiovascular risk beyond eGFR or albumin-to-creatinine ratio. Background: CKD is strongly associated with cardiovascular disease (CVD), yet the etiology responsible for this link remains elusive. Novel blood and urine biomarkers reflecting kidney tubule dysfunction and injury may provide novel insights to mechanisms linking the kidney to CVD. Methods: In 470 participants of the Multi-Ethnic Study of Atherosclerosis without type 2 diabetes, CVD, or CKD, we measured six plasma (kidney injury molecule-1 [KIM-1], monocyte chemoattractant protein-1, soluble urokinase plasminogen activator receptor, tumor necrosis factor receptor 1 and 2, and anti–chitinase-3-like protein 1) and six urinary ( α 1 microglobulin, EGF, KIM-1, monocyte chemoattractant protein-1, anti–chitinase-3-like protein 1, and uromodulin) kidney tubule health biomarkers. To assess microvascular health, we used retinal microvascular measurements assessed from fundus photography: central retinal arteriolar and venular equivalents (central retinal artery equivalent [CRAE] and central retinal venular equivalent [CRVE], respectively). Multivariable linear regression evaluated associations of tubule biomarkers and kidney function with CRAE and CRVE. Results: The mean participant age was 60±10 years with 52% female. The racial and ethnic distribution was 46% White, 24% Black, 18% Hispanic, and 11% Chinese. The mean eGFR was 92.1±13.3 ml/min per 1.73 m 2 , and the median urine albumin-to-creatinine ratio was 4.7 mg/g (interquartile range, 3.0–9.4). Higher plasma KIM-1 ( β , −5.14; 95% confidence interval [CI], −9.84 to −0.45) and urine KIM-1 ( β, −5.68; 95% CI, −10.15 to −1.22) concentrations were individually associated with narrower CRAE, while plasma soluble urokinase plasminogen activator receptor concentrations were individually associated with wider CRAE ( β , 9.15; 95% CI, 0.89 to 17.4) and CRVE ( β , 21.49; 95% CI, 9.39 to 33.59). There were no significant associations between the remaining tubule health biomarkers and CRAE or CRVE nor were there associations between eGFR or urine albumin-to-creatinine ratio with CRAE and CRVE. Conclusions: In this study of community-living individuals without CKD, diabetes, or CVD, selected kidney tubule health markers are associated with retinal microvascular changes. These findings suggest that kidney tubule biomarkers may reflect or contribute to systemic microvascular dysfunction, above and beyond glomerular damage. Tubular biomarkers may help elucidate the shared microvascular mechanisms linking CKD and CVD.


  • Open Access

    The Impact of a Wearable Activity Tracker and Structured Feedback Program on Physical Activity in Hemodialysis Patients: The Step4Life Pilot Randomized Controlled Trial

    by Rakesh Malhotra, Sina Rahimi, Ushma Agarwal, Ronit Katz, Ujjala Kumar, Pranav S. Garimella, Vineet Gupta, Tushar Chopra, Peter Kotanko, T. Alp Ikizler, et al.


  • Physical activity in hemodialysis patients on nondialysis and dialysis days: Prospective observational study

    by Rakesh Malhotra, Ujjala Kumar, Patricia Virgen, Bryan Magallon, Pranav S. Garimella, Tushar Chopra, Peter Kotanko, T. Alp Ikizler, Danuta Trzebinska, Lisa Cadmus‐Bertram, et al.

    Introduction: The physical decline in patients with end‐stage kidney disease (ESKD) is associated with morbidity and mortality. Prior studies have attempted to promote physical activity at the time of dialysis; however, physical activity patterns on the nondialysis days are unknown. This study aimed to quantify physical activity on dialysis and nondialysis days in hemodialysis patients using a wearable actigraph.Methods: In this prospective study, subjects receiving hemodialysis were recruited from two outpatient dialysis units in urban San Diego and rural Imperial County, CA, between March 2018 and April 2019. Key inclusion criteria included: (1) receiving thrice weekly hemodialysis for ≥3 months, (2) age ≥ 18 years, and (3) able to walk with or without assistive devices. All participants wore a Fitbit Charge 2 tracker for a minimum of 4 weeks. The primary outcome was the number of steps per day. Each participant completed the Physical Activity Questionnaire, the Patient Health Questionnaire (PHQ)‐9, the PROMIS Short form Fatigue Questionnaire at baseline, and the Participant Technology Experience Questionnaire at day 7 after study enrolment.Findings: Of the 52 recruited, 45 participants (urban = 25; rural = 20) completed the study. The mean age was 61 ± 15 years, 42% were women, 64% were Hispanic, and the mean dialysis vintage was 4.4 ± 3.0 years. For those with valid Fitbit data (defined as ≥10 hours of wear per day) for 28 days (n = 45), participants walked an average of 3688 steps per day, and 73% of participants were sedentary (80 years were less active than younger (age < 65 years) participants (1232 vs. 4529 steps, P = 0.01). There were no statistical differences between the groups when stratified by gender (women vs. men [2817 vs. 4324 steps, respectively]), urbanicity (rural vs. urban dialysis unit [3141 vs. 4123 steps, respectively]), and dialysis/nondialysis day (3177 vs. 4133 steps, respectively). Due to the small sample size, we also calculated effect sizes. The effect size was medium for the gender differences (cohen's d = 0.57) and small to medium for urbanicity and dialysis/nondialysis day (d = 0.37 and d = 0.33, respectively). We found no association between physical activity and self‐reported depression and fatigue scale. The majority of participants (62%, 28/45) found the Fitbit tracker easy to wear and comfortable.Discussion: ESKD participants receiving hemodialysis are frequently sedentary, and differences appear more pronounced in older patients. These findings may assist in designing patient‐centered interventions to increase physical activity among hemodialysis patients.